Jazz Pharma Plc (JAZZ) 150.53 $JAZZ
Covered Call reports for Marathon Oil Corporation, Amazon.com, Jazz Pharmaceuticals, Kellogg Company and Nike include trade ideas that offer returns of 20% or more!
PR Newswire - Fri Jul 29, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for AMZN, JAZZ, K, MRO, and NKE.
AMZN: 767.74 (+8.93), NKE: 55.41 (-0.09), JAZZ: 150.53 (-0.44), MRO: 12.92 (-0.72), K: 82.37 (-0.34)
Jazz Pharmaceuticals and Pfenex Enter into a Worldwide License and Option Agreement Related to Product Candidates in Early Development for Hematological Malignancies
PR Newswire Europe - Thu Jul 28, 3:06PM CDT
Jazz Pharmaceuticals plc and Pfenex Inc. today announced an agreement under which Pfenex granted Jazz Pharmaceuticals worldwide rights to develop and commercialize multiple early stage hematology product candidates. The agreement also includes an option for Jazz Pharmaceuticals to negotiate a license for a recombinant pegaspargase product candidate with Pfenex. This early development stage collaboration demonstrates Jazz Pharmaceuticals' focus on identifying innovative technologies that may lead to the development of important therapeutic options for patients with hematological malignancies.
JAZZ: 150.53 (-0.44), PFNX: 8.60 (+0.53)
Look for Shares of Jazz Pharmaceuticals to Potentially Rebound after Yesterday's 1.06% Sell Off
Comtex SmarTrend(R) - Mon Jul 25, 4:23PM CDT
Jazz Pharmaceuticals (NASDAQ:JAZZ) traded in a range yesterday that spanned from a low of $140.30 to a high of $142.02. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $140.79 on volume of 226,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
JAZZ: 150.53 (-0.44)
Jazz Pharmaceuticals to Report 2016 Second Quarter Financial Results on August 9, 2016
PR Newswire Europe - Mon Jul 25, 3:06PM CDT
Jazz Pharmaceuticals plc today announced that it will report its 2016 second quarter financial results on Tuesday, August 9, 2016, after the close of the financial markets. Company management will host a live audio webcast immediately following the announcement at 4:30 p.m. EDT/9:30 p.m. IST to discuss second quarter 2016 financial results and provide a business and financial update.
JAZZ: 150.53 (-0.44)
Jazz Pharmaceuticals plc Announces Results of Tender Offer to Purchase All of The Outstanding Shares of Common Stock of Celator Pharmaceuticals, Inc.
PR Newswire Europe - Tue Jul 12, 12:50AM CDT
Jazz Pharmaceuticals plc today announced the results of its tender offer to purchase all of the outstanding shares of common stock of Celator Pharmaceuticals, Inc. at $30.25 per share, net to the seller in cash, without interest (less any required withholding taxes). The tender offer is being effected by Jazz Pharmaceuticals' indirect wholly-owned subsidiary, Plex Merger Sub, Inc.
CPXX: 30.24 (unch), JAZZ: 150.53 (-0.44)
After Yesterday's Decline of 2.80%, Jazz Pharmaceuticals Offers Investors Better Value
Comtex SmarTrend(R) - Tue Jun 21, 2:18PM CDT
Jazz Pharmaceuticals (NASDAQ:JAZZ) traded in a range yesterday that spanned from a low of $139.52 to a high of $144.95. Yesterday, the shares fell 2.8%, which took the trading range below the 3-day low of $142.42 on volume of 400,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
JAZZ: 150.53 (-0.44)
Watch for Jazz Pharmaceuticals to Potentially Rebound After Falling 1.10% Yesterday
Comtex SmarTrend(R) - Fri Jun 17, 2:51PM CDT
Jazz Pharmaceuticals (NASDAQ:JAZZ) traded in a range yesterday that spanned from a low of $142.42 to a high of $146.74. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $143.66 on volume of 267,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
JAZZ: 150.53 (-0.44)
Jazz Pharmaceuticals Offers HAL Study Data on JZP-110
Zacks Equity Research - Zacks Investment Research - Wed Jun 15, 8:42AM CDT
Jazz (JAZZ) presented new data from a Human Abuse Liability (HAL) study on JZP-110 at the annual meeting of the Associated Professional Sleep Societies.
ANIP: 61.06 (+0.46), JAZZ: 150.53 (-0.44), PFE: 37.31 (+0.42), BMY: 76.19 (+1.38)
Jazz Pharmaceuticals Presents New Data from a Human Abuse Liability (HAL) Study for JZP-110, an Investigational Treatment for Excessive Sleepiness in Patients with Narcolepsy or with Obstructive Sleep Apnea, at 30th Annual SLEEP Meeting
PR Newswire Europe - Tue Jun 14, 8:05AM CDT
Jazz Pharmaceuticals plc today announced results from a Human Abuse Liability (HAL) study of JZP-110, an investigational wake-promoting agent in Phase 3 development for the treatment of excessive sleepiness (ES) in adult patients with narcolepsy or with obstructive sleep apnea (OSA). The data will be presented today at the 30th Associated Professional Sleep Societies (APSS) Annual SLEEP Meeting, taking place June 11-15, 2016 in Denver, Colorado.
JAZZ: 150.53 (-0.44)
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of The Board of Directors of Celator Pharmaceuticals, Inc. - CPXX
ACCESSWIRE - Wed Jun 08, 5:36PM CDT
BALA CYNWYD, PA / ACCESSWIRE / June 8, 2016 / Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Celator Pharmaceuticals, Inc. ("Celator" or "the Company"
(Nasdaq: CPXX) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Jazz Pharmaceuticals plc, ("Jazz".
CPXX: 30.24 (unch), JAZZ: 150.53 (-0.44)
Biotechnology Equities Technical Notes -- Grifols, Achillion Pharma, Jazz Pharma, and Puma Biotechnology
PR Newswire - Wed Jun 08, 7:25AM CDT
On Tuesday, June 07, 2016, the NASDAQ Composite ended the trading session at 4,961.75, down 0.14%; the Dow Jones Industrial Average advanced 0.10% to finish at 17,938.28; and the S&P 500 closed at 2,112.13, up 0.13%. The gains were broad based as eight out of nine sectors ended the session in positive. ActiveWallSt.com has initiated coverage on the following equities: Grifols S.A. (NASDAQ: GRFS), Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), Jazz Pharmaceuticals PLC (NASDAQ: JAZZ), and Puma Biotechnology Inc. (NYSE: PBYI). Learn more about these stocks by accessing their free trade alerts at:
ACHN: 8.43 (+0.15), JAZZ: 150.53 (-0.44), GRFS: 16.76 (-0.18), PBYI: 49.04 (-0.85)
Celator Pharmaceuticals, Inc. Acquisition May Not Be in the Best Interests of CPXX Shareholders
PR Newswire - Fri Jun 03, 5:21PM CDT
WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Celator Pharmaceuticals, Inc. ("CPXX" or the "Company" in connection with the proposed acquisition of the Company by Jazz Pharmaceuticals plc ("Jazz". On May 31, 2016, the Company announced it had reached a definitive agreement for Jazz to acquire all outstanding shares of CPXX pursuant to a tender offer for $30.25 in cash for each share of Company common stock.
CPXX: 30.24 (unch), JAZZ: 150.53 (-0.44)
Plasminogen Activator Inhibitor-1 (Endothelial Plasminogen Activator Inhibitor or Serpin E1 or PAI-1) - Pipeline Review, H1 2016 Featuring D-Pharm Ltd. & Jazz Pharmaceuticals Plc - Research and Markets
BusinessWire - Fri Jun 03, 10:52AM CDT
Research and Markets has announced the addition of the "Plasminogen Activator Inhibitor-1 (Endothelial Plasminogen Activator Inhibitor or Serpin E1 or PAI-1) - Pipeline Review, H1 2016" report to their offering.
JAZZ: 150.53 (-0.44)
Jazz Pharmaceuticals Partnering Deals and Alliances 2010 to 2016
PR Newswire - Thu Jun 02, 6:19PM CDT
The Partnering Deals and Alliance since 2010 report provides an in-depth insight into the partnering activity of one of the world's leading life sciences companies.
JAZZ: 150.53 (-0.44)
CELATOR PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe and Powers Taylor LLP Investigate Sale to Jazz Pharmaceuticals plc
BusinessWire - Thu Jun 02, 12:22PM CDT
Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Celator Pharmaceuticals, Inc. ("Celator" (NASDAQ: CPXX) concerning the sale to Jazz Pharmaceuticals plc. Under the terms of the agreement, Celator shareholders will only receive $30.25 in cash for each share owned.
CPXX: 30.24 (unch), JAZZ: 150.53 (-0.44)
Company News for June 01, 2016
Zacks Equity Research - Zacks Investment Research - Wed Jun 01, 9:10AM CDT
Companies in the News are: WR,GXP,MDT,CPXX,JAZZ,VLKAY
CPXX: 30.24 (unch), GXP: 29.70 (-0.08), WR: 55.42 (-0.15), MDT: 88.06 (+0.43), JAZZ: 150.53 (-0.44)
Covered Call reports for Marathon Oil Corporation, Amazon.com, Jazz Pharmaceuticals, Kellogg Company and Nike include trade ideas that offer returns of 20% or more!
PR Newswire - Fri Jul 29, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for AMZN, JAZZ, K, MRO, and NKE.
AMZN: 767.74 (+8.93), NKE: 55.41 (-0.09), JAZZ: 150.53 (-0.44), MRO: 12.92 (-0.72), K: 82.37 (-0.34)
Jazz Pharmaceuticals and Pfenex Enter into a Worldwide License and Option Agreement Related to Product Candidates in Early Development for Hematological Malignancies
PR Newswire Europe - Thu Jul 28, 3:06PM CDT
Jazz Pharmaceuticals plc and Pfenex Inc. today announced an agreement under which Pfenex granted Jazz Pharmaceuticals worldwide rights to develop and commercialize multiple early stage hematology product candidates. The agreement also includes an option for Jazz Pharmaceuticals to negotiate a license for a recombinant pegaspargase product candidate with Pfenex. This early development stage collaboration demonstrates Jazz Pharmaceuticals' focus on identifying innovative technologies that may lead to the development of important therapeutic options for patients with hematological malignancies.
JAZZ: 150.53 (-0.44), PFNX: 8.60 (+0.53)
Look for Shares of Jazz Pharmaceuticals to Potentially Rebound after Yesterday's 1.06% Sell Off
Comtex SmarTrend(R) - Mon Jul 25, 4:23PM CDT
Jazz Pharmaceuticals (NASDAQ:JAZZ) traded in a range yesterday that spanned from a low of $140.30 to a high of $142.02. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $140.79 on volume of 226,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
JAZZ: 150.53 (-0.44)
Jazz Pharmaceuticals to Report 2016 Second Quarter Financial Results on August 9, 2016
PR Newswire Europe - Mon Jul 25, 3:06PM CDT
Jazz Pharmaceuticals plc today announced that it will report its 2016 second quarter financial results on Tuesday, August 9, 2016, after the close of the financial markets. Company management will host a live audio webcast immediately following the announcement at 4:30 p.m. EDT/9:30 p.m. IST to discuss second quarter 2016 financial results and provide a business and financial update.
JAZZ: 150.53 (-0.44)
Jazz Pharmaceuticals plc Announces Results of Tender Offer to Purchase All of The Outstanding Shares of Common Stock of Celator Pharmaceuticals, Inc.
PR Newswire Europe - Tue Jul 12, 12:50AM CDT
Jazz Pharmaceuticals plc today announced the results of its tender offer to purchase all of the outstanding shares of common stock of Celator Pharmaceuticals, Inc. at $30.25 per share, net to the seller in cash, without interest (less any required withholding taxes). The tender offer is being effected by Jazz Pharmaceuticals' indirect wholly-owned subsidiary, Plex Merger Sub, Inc.
CPXX: 30.24 (unch), JAZZ: 150.53 (-0.44)
After Yesterday's Decline of 2.80%, Jazz Pharmaceuticals Offers Investors Better Value
Comtex SmarTrend(R) - Tue Jun 21, 2:18PM CDT
Jazz Pharmaceuticals (NASDAQ:JAZZ) traded in a range yesterday that spanned from a low of $139.52 to a high of $144.95. Yesterday, the shares fell 2.8%, which took the trading range below the 3-day low of $142.42 on volume of 400,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
JAZZ: 150.53 (-0.44)
Watch for Jazz Pharmaceuticals to Potentially Rebound After Falling 1.10% Yesterday
Comtex SmarTrend(R) - Fri Jun 17, 2:51PM CDT
Jazz Pharmaceuticals (NASDAQ:JAZZ) traded in a range yesterday that spanned from a low of $142.42 to a high of $146.74. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $143.66 on volume of 267,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
JAZZ: 150.53 (-0.44)
Jazz Pharmaceuticals Offers HAL Study Data on JZP-110
Zacks Equity Research - Zacks Investment Research - Wed Jun 15, 8:42AM CDT
Jazz (JAZZ) presented new data from a Human Abuse Liability (HAL) study on JZP-110 at the annual meeting of the Associated Professional Sleep Societies.
ANIP: 61.06 (+0.46), JAZZ: 150.53 (-0.44), PFE: 37.31 (+0.42), BMY: 76.19 (+1.38)
Jazz Pharmaceuticals Presents New Data from a Human Abuse Liability (HAL) Study for JZP-110, an Investigational Treatment for Excessive Sleepiness in Patients with Narcolepsy or with Obstructive Sleep Apnea, at 30th Annual SLEEP Meeting
PR Newswire Europe - Tue Jun 14, 8:05AM CDT
Jazz Pharmaceuticals plc today announced results from a Human Abuse Liability (HAL) study of JZP-110, an investigational wake-promoting agent in Phase 3 development for the treatment of excessive sleepiness (ES) in adult patients with narcolepsy or with obstructive sleep apnea (OSA). The data will be presented today at the 30th Associated Professional Sleep Societies (APSS) Annual SLEEP Meeting, taking place June 11-15, 2016 in Denver, Colorado.
JAZZ: 150.53 (-0.44)
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of The Board of Directors of Celator Pharmaceuticals, Inc. - CPXX
ACCESSWIRE - Wed Jun 08, 5:36PM CDT
BALA CYNWYD, PA / ACCESSWIRE / June 8, 2016 / Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Celator Pharmaceuticals, Inc. ("Celator" or "the Company"
(Nasdaq: CPXX) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Jazz Pharmaceuticals plc, ("Jazz". CPXX: 30.24 (unch), JAZZ: 150.53 (-0.44)
Biotechnology Equities Technical Notes -- Grifols, Achillion Pharma, Jazz Pharma, and Puma Biotechnology
PR Newswire - Wed Jun 08, 7:25AM CDT
On Tuesday, June 07, 2016, the NASDAQ Composite ended the trading session at 4,961.75, down 0.14%; the Dow Jones Industrial Average advanced 0.10% to finish at 17,938.28; and the S&P 500 closed at 2,112.13, up 0.13%. The gains were broad based as eight out of nine sectors ended the session in positive. ActiveWallSt.com has initiated coverage on the following equities: Grifols S.A. (NASDAQ: GRFS), Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), Jazz Pharmaceuticals PLC (NASDAQ: JAZZ), and Puma Biotechnology Inc. (NYSE: PBYI). Learn more about these stocks by accessing their free trade alerts at:
ACHN: 8.43 (+0.15), JAZZ: 150.53 (-0.44), GRFS: 16.76 (-0.18), PBYI: 49.04 (-0.85)
Celator Pharmaceuticals, Inc. Acquisition May Not Be in the Best Interests of CPXX Shareholders
PR Newswire - Fri Jun 03, 5:21PM CDT
WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Celator Pharmaceuticals, Inc. ("CPXX" or the "Company"
in connection with the proposed acquisition of the Company by Jazz Pharmaceuticals plc ("Jazz". On May 31, 2016, the Company announced it had reached a definitive agreement for Jazz to acquire all outstanding shares of CPXX pursuant to a tender offer for $30.25 in cash for each share of Company common stock. CPXX: 30.24 (unch), JAZZ: 150.53 (-0.44)
Plasminogen Activator Inhibitor-1 (Endothelial Plasminogen Activator Inhibitor or Serpin E1 or PAI-1) - Pipeline Review, H1 2016 Featuring D-Pharm Ltd. & Jazz Pharmaceuticals Plc - Research and Markets
BusinessWire - Fri Jun 03, 10:52AM CDT
Research and Markets has announced the addition of the "Plasminogen Activator Inhibitor-1 (Endothelial Plasminogen Activator Inhibitor or Serpin E1 or PAI-1) - Pipeline Review, H1 2016" report to their offering.
JAZZ: 150.53 (-0.44)
Jazz Pharmaceuticals Partnering Deals and Alliances 2010 to 2016
PR Newswire - Thu Jun 02, 6:19PM CDT
The Partnering Deals and Alliance since 2010 report provides an in-depth insight into the partnering activity of one of the world's leading life sciences companies.
JAZZ: 150.53 (-0.44)
CELATOR PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe and Powers Taylor LLP Investigate Sale to Jazz Pharmaceuticals plc
BusinessWire - Thu Jun 02, 12:22PM CDT
Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Celator Pharmaceuticals, Inc. ("Celator"
(NASDAQ: CPXX) concerning the sale to Jazz Pharmaceuticals plc. Under the terms of the agreement, Celator shareholders will only receive $30.25 in cash for each share owned. CPXX: 30.24 (unch), JAZZ: 150.53 (-0.44)
Company News for June 01, 2016
Zacks Equity Research - Zacks Investment Research - Wed Jun 01, 9:10AM CDT
Companies in the News are: WR,GXP,MDT,CPXX,JAZZ,VLKAY
CPXX: 30.24 (unch), GXP: 29.70 (-0.08), WR: 55.42 (-0.15), MDT: 88.06 (+0.43), JAZZ: 150.53 (-0.44)
